Lu-177 dotatate plus olaparib for inoperable neuroendocrine tumors
Treatments studied
Part of Cancer clinical trials.
This study tests whether combining Lu-177 dotatate (a targeted radiation treatment) with olaparib (a targeted pill) can shrink or slow growth of inoperable gastroenteropancreatic neuroendocrine tumors. It’s designed for tumors that show the right “targets” on a special scan and that have started to progress despite standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a gastroenteropancreatic neuroendocrine tumor confirmed by tumor tissue testing.
- Your cancer cannot be removed with curative surgery (for example, it’s metastatic or locally advanced into key areas).
- Your tumor must show somatostatin receptors on a Ga-68 dotatate PET scan within the last 12 weeks.
- Your scans must show progressive disease within the last 36 months (and you need at least one measurable spot).
- You must be able to take study pills by mouth, and your general health and blood counts must meet specific thresholds.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies Lu-177 DOTATATE (Lutathera), a targeted radiation medicine, for tumors that cannot be safely removed with surgery. It aims to shrink or control pheochromocytoma/paraganglioma that is showing recent growth and has a specific target signal on a special PET scan.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This early-phase study tests whether adding a medicine called a PARP inhibitor to peptide receptor radionuclide therapy (PRRT) can better control advanced or metastatic neuroendocrine tumors (NET). It may help by targeting tumor DNA repair while PRRT delivers targeted radiation.
This trial tests a type of radiation therapy called Lu-177 Dotatoc (PRRT) for people with neuroendocrine tumors or other cancers that have high levels of a specific protein (sst2). It may be an option when standard treatments stop working or aren't available.
This Phase 1 study tests how safe and effective it is to combine a PARP inhibitor (a targeted cancer medicine) with PRRT, a treatment that delivers radiation directly to certain tumor cells. It is for people with grade 2 neuroendocrine tumors from the pancreas or intestines, especially when scans suggest the tumor will take up the targeted radiation.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.